Giuseppe Boriani1, Christian T Ruff2, Julia F Kuder2, Minggao Shi3, Hans J Lanz4, Elliott M Antman2, Eugene Braunwald2, Robert P Giugliano2. 1. Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena & Reggio Emilia, Modena University Hospital, Modena, Italy. 2. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States. 3. Daiichi Sankyo Inc., Basking Ridge, New Jersey, United States. 4. Daiichi Sankyo Europe GmbH, Munich, Germany.
Abstract
BACKGROUND: The effects of anticoagulants at extremes of body weight (BW) are not well described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics and clinical outcomes in patients randomized towarfarin, higher dose edoxaban (HDER), and lower dose edoxaban (LDER) regimens at extremes of BW in ENGAGE AF-TIMI 48. METHODS AND RESULTS: We analyzed three BW groups: low BW (LBW: <5th percentile, ≤55 kg, N = 1,082), middle BW (MBW: 45th-55th percentile, 79.8-84 kg, N = 2,153), and high BW (HBW: >95th percentile, ≥120 kg, N = 1,093). In the warfarin arm, LBW patients had higher rates of stroke/systemic embolism (SSE: 6.5 vs. 4.7 in MBW vs. 1.6% in HBW, P trend < 0.001), major bleeding (MB: 9.3 vs. 7.7 vs. 6.5%, P trend = 0.08), and worse net clinical outcome of systemic embolic event, MB, or death (31.5 vs. 19.1 vs. 16.0%, P trend < 0.0001). The time-in-therapeutic range with warfarin was lowest in LBW patients (63.0 vs. 69.3 vs. 70.1% patients, P trend < 0.001). The pharmacokinetic/pharmacodynamic profile of edoxaban was consistent across BW groups. The risk of SSE was similar between HDER and warfarin for each of the three weight groups (P int = 0.52, P int-trend = 0.86). MB was reduced by LDER versus warfarin (P int = 0.061, P int-trend = 0.023), especially in LBW patients. Net clinical outcomes were improved by HDER versus warfarin (P int = 0.087, P int-trend = 0.027), especially in LBW patients. CONCLUSION: Patients with LBW in ENGAGE AF-TIMI 48 had in general a more fragile clinical status and poorer international normalized ratio control. The pharmacokinetic/pharmacodynamic profile of edoxaban was consistent across extremes of BW, resulting in similar efficacy compared with warfarin, while major or clinically relevant non-MB and net outcomes were most favorable with edoxaban as compared to warfarin in LBW patients. Thieme. All rights reserved.
RCT Entities:
BACKGROUND: The effects of anticoagulants at extremes of body weight (BW) are not well described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics and clinical outcomes in patients randomized to warfarin, higher dose edoxaban (HDER), and lower dose edoxaban (LDER) regimens at extremes of BW in ENGAGE AF-TIMI 48. METHODS AND RESULTS: We analyzed three BW groups: low BW (LBW: <5th percentile, ≤55 kg, N = 1,082), middle BW (MBW: 45th-55th percentile, 79.8-84 kg, N = 2,153), and high BW (HBW: >95th percentile, ≥120 kg, N = 1,093). In the warfarin arm, LBW patients had higher rates of stroke/systemic embolism (SSE: 6.5 vs. 4.7 in MBW vs. 1.6% in HBW, P trend < 0.001), major bleeding (MB: 9.3 vs. 7.7 vs. 6.5%, P trend = 0.08), and worse net clinical outcome of systemic embolic event, MB, or death (31.5 vs. 19.1 vs. 16.0%, P trend < 0.0001). The time-in-therapeutic range with warfarin was lowest in LBW patients (63.0 vs. 69.3 vs. 70.1% patients, P trend < 0.001). The pharmacokinetic/pharmacodynamic profile of edoxaban was consistent across BW groups. The risk of SSE was similar between HDER and warfarin for each of the three weight groups (P int = 0.52, P int-trend = 0.86). MB was reduced by LDER versus warfarin (P int = 0.061, P int-trend = 0.023), especially in LBW patients. Net clinical outcomes were improved by HDER versus warfarin (P int = 0.087, P int-trend = 0.027), especially in LBW patients. CONCLUSION:Patients with LBW in ENGAGE AF-TIMI 48 had in general a more fragile clinical status and poorer international normalized ratio control. The pharmacokinetic/pharmacodynamic profile of edoxaban was consistent across extremes of BW, resulting in similar efficacy compared with warfarin, while major or clinically relevant non-MB and net outcomes were most favorable with edoxaban as compared to warfarin in LBW patients. Thieme. All rights reserved.
Authors: Anthony P Carnicelli; Hwanhee Hong; Stuart J Connolly; John Eikelboom; Robert P Giugliano; David A Morrow; Manesh R Patel; Lars Wallentin; John H Alexander; M Cecilia Bahit; Alexander P Benz; Erin A Bohula; Tze-Fan Chao; Leanne Dyal; Michael Ezekowitz; Keith A A Fox; Baris Gencer; Jonathan L Halperin; Ziad Hijazi; Stefan H Hohnloser; Kaiyuan Hua; Elaine Hylek; Eri Toda Kato; Julia Kuder; Renato D Lopes; Kenneth W Mahaffey; Jonas Oldgren; Jonathan P Piccini; Christian T Ruff; Jan Steffel; Daniel Wojdyla; Christopher B Granger Journal: Circulation Date: 2022-01-05 Impact factor: 29.690
Authors: Alison R Novak; Courtney Shakowski; Toby C Trujillo; Garth C Wright; Scott W Mueller; Tyree H Kiser Journal: J Thromb Thrombolysis Date: 2022-06-10 Impact factor: 5.221
Authors: Thomas A Zelniker; Maddalena Ardissino; Felicita Andreotti; Michelle L O'Donoghue; Ophelia Yin; Jeong-Gun Park; Sabina A Murphy; Christian T Ruff; Hans J Lanz; Elliott M Antman; Eugene Braunwald; Robert P Giugliano; Piera Angelica Merlini Journal: Circulation Date: 2021-02-15 Impact factor: 29.690